Despite recent setbacks, drug makers and investors are still optimistic about finding an Alzheimer disease treatment; the United States' already moderately severe flu season could get worse; a charity that assists patients with out-of-pocket drug costs is suing the government over communication restrictions with drug donors.
Although there have been recent setbacks in the search to treat Alzheimer disease, drug makers and investors are still optimistic. According to The Wall Street Journal, Roche, Biogen, Eli Lilly, and more are still working on their Alzheimer treatments even as Axovant Sciences and Pfizer both gave up on their work. In fiscal year 2017, the National Institutes of Health will have invested almost triple what it did in 2013 in Alzheimer disease. Analysts expect that a successful treatment could be worth billions of dollars.
While the flu season in the United States is already “moderately severe,” it could get even worse. The majority of cases have been a strain that caused many hospitalizations and deaths during Australia’s winter 6 months ago, reported The New York Times. The combination of the virus strain, an imperfect vaccine, and the cold weather could all combine to make the flu season worse. The United States expects that the flu shot this season is roughly 30% effective against the current virus strain.
Patient Services Inc, which offers assistance to patients on out-of-pocket drug costs, has sued the federal government over donor communications. New guidance from the Office of the Inspector General requires that the charity refrain from communicating with drug makers who donate to provide patients assistance in order to get information about issues with patient populations and drug costs used to create programs, reported Reuters. The charity claims the restrictions are “unreasonable, unfair, and unconstitutional.”
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
Study Links COVID-19 Pandemic to Rise in Neoadjuvant Chemotherapy for Ovarian Cancer in US
April 17th 2024There was greater use of neoadjuvant chemotherapy among US patients with ovarian cancer (OC) during the COVID-19 pandemic to reduce potential COVID-19 exposure and cancer treatment-related complications.
Read More